In June 2006, the tyrosine kinase inhibitor dasatinib (Sprycel; Bristol-Myers Squibb) was approved by the US FDA for the treatment of adults with chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia with resistance or intolerance to previous therapy, including the kinase inhibitor imatinib (Gleevec; Novartis).
This is a preview of subscription content, log in via an institution to check access.
References
Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330–1340 (1999).
Capdeville, R. et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493–502 (2002).
Shah, N. P. et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004).
Tokarski, J. S. et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790–5797 (2006).
Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
FDA labelling information, [online] (2006).
Ptasznik, A. et al. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR–ABL1(+) leukemia cells. Nature Med. 10, 1187–1189 (2004).
Donato, N. J. et al. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690–698 (2003).
Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR–ABL positive cells. Nature Med. 2, 561–566 (1996).
Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542–2551 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kantarjian, H., Jabbour, E., Grimley, J. et al. Dasatinib. Nat Rev Drug Discov 5, 717–718 (2006). https://doi.org/10.1038/nrd2135
Issue Date:
DOI: https://doi.org/10.1038/nrd2135
- Springer Nature Limited
This article is cited by
-
Cancer Therapies and Vascular Toxicities
Current Treatment Options in Oncology (2022)
-
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
Molecular and Cellular Biochemistry (2022)
-
Synthesis and biological evaluation of new thiazolyl-urea derivatives as potential dual C-RAF/FLT3 inhibitors
Medicinal Chemistry Research (2022)
-
Kinase drug discovery 20 years after imatinib: progress and future directions
Nature Reviews Drug Discovery (2021)
-
Cellular Senescence in Idiopathic Pulmonary Fibrosis
Current Molecular Biology Reports (2021)